Latest Krensavage Asset Management, LLC Stock Portfolio
Krensavage Asset Management, LLC Performance:
2024 Q3: 2.94%YTD: 7.2%2023: -2.22%
Performance for 2024 Q3 is 2.94%, and YTD is 7.2%, and 2023 is -2.22%.
About Krensavage Asset Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Krensavage Asset Management, LLC reported an equity portfolio of $178.5 Millions as of 30 Sep, 2024.
The top stock holdings of Krensavage Asset Management, LLC are UTHR, EXEL, CAH. The fund has invested 20.1% of it's portfolio in UNITED THERAPEUTICS CORP and 18.6% of portfolio in EXELIXIS INC.
The fund managers got completely rid off TARO PHARMACEUTICAL INDUS stocks. They significantly reduced their stock positions in REGENERON PHARMACEUTICALS (REGN), VANDA PHARMACEUTICALS INC (VNDA) and BIONTECH SE-ADR. Krensavage Asset Management, LLC opened new stock positions in INDIVIOR PLC. The fund showed a lot of confidence in some stocks as they added substantially to ENANTA PHARMACEUTICALS INC (ENTA), MURAL ONCOLOGY PLC and JAZZ PHARMACEUTICALS PLC (JAZZ).
The top stock holdings of Krensavage Asset Management, LLC are UTHR, EXEL, CAH. The fund has invested 20.1% of it's portfolio in UNITED THERAPEUTICS CORP and 18.6% of portfolio in EXELIXIS INC.
The fund managers got completely rid off TARO PHARMACEUTICAL INDUS stocks. They significantly reduced their stock positions in REGENERON PHARMACEUTICALS (REGN), VANDA PHARMACEUTICALS INC (VNDA) and BIONTECH SE-ADR. Krensavage Asset Management, LLC opened new stock positions in INDIVIOR PLC. The fund showed a lot of confidence in some stocks as they added substantially to ENANTA PHARMACEUTICALS INC (ENTA), MURAL ONCOLOGY PLC and JAZZ PHARMACEUTICALS PLC (JAZZ).
Krensavage Asset Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Krensavage Asset Management, LLC made a return of 2.94% in the last quarter. In trailing 12 months, it's portfolio return was 9.66%.
New Buys
| Ticker | $ Bought |
|---|---|
| indivior plc | 6,843,000 |
New stocks bought by Krensavage Asset Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| enanta pharmaceuticals inc | 19.72 |
| jazz pharmaceuticals plc | 1.08 |
| mural oncology plc | 1.08 |
Additions to existing portfolio by Krensavage Asset Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| regeneron pharmaceuticals | -95.5 |
| vanda pharmaceuticals inc | -37.37 |
| biontech se-adr | -29.26 |
| exelixis inc | -23.6 |
| united therapeutics corp | -15.12 |
| biogen inc | -8.31 |
| cardinal health inc | -3.4 |
| sanofi-adr | -2.36 |
Krensavage Asset Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| taro pharmaceutical indus | -27,954,000 |
Krensavage Asset Management, LLC got rid off the above stocks
Sector Distribution
Krensavage Asset Management, LLC has about 85% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 85 |
| Others | 15 |
Market Cap. Distribution
Krensavage Asset Management, LLC has about 45.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 45.7 |
| MID-CAP | 29.5 |
| UNALLOCATED | 15 |
| MICRO-CAP | 8.7 |
| SMALL-CAP | 1.1 |
Stocks belong to which Index?
About 39.3% of the stocks held by Krensavage Asset Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 60.7 |
| S&P 500 | 25.6 |
| RUSSELL 2000 | 13.7 |
Krensavage Asset Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Krensavage Asset Management, LLC
Krensavage Asset Management, LLC has 13 stocks in it's portfolio. About 98.6% of the portfolio is in top 10 stocks. BIIB proved to be the most loss making stock for the portfolio. EXEL was the most profitable stock for Krensavage Asset Management, LLC last quarter.
Last Reported on: 15 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALKS | alkermes plc | 3.94 | 251,495 | 7,039,000 | reduced | -2.35 | ||
| BIIB | biogen inc | 12.33 | 113,502 | 22,001,000 | reduced | -8.31 | ||
| CAH | cardinal health inc | 13.02 | 210,263 | 23,238,000 | reduced | -3.4 | ||
| ENTA | enanta pharmaceuticals inc | 8.70 | 1,498,070 | 15,520,000 | added | 19.72 | ||
| EXEL | exelixis inc | 18.64 | 1,281,610 | 33,258,000 | reduced | -23.6 | ||
| JAZZ | jazz pharmaceuticals plc | 6.88 | 110,257 | 12,284,000 | added | 1.08 | ||
| REGN | regeneron pharmaceuticals | 0.21 | 353 | 371,000 | reduced | -95.5 | ||
| UTHR | united therapeutics corp | 20.15 | 100,332 | 35,954,000 | reduced | -15.12 | ||
| VNDA | vanda pharmaceuticals inc | 1.09 | 414,684 | 1,945,000 | reduced | -37.37 | ||
| biontech se-adr | 6.23 | 93,583 | 11,115,000 | reduced | -29.26 | |||
| sanofi-adr | 4.85 | 150,205 | 8,656,000 | reduced | -2.36 | |||
| indivior plc | 3.83 | 701,873 | 6,843,000 | new | ||||
| mural oncology plc | 0.13 | 75,868 | 237,000 | added | 1.08 | |||
| taro pharmaceutical indus | 0.00 | 0.00 | 0.00 | sold off | -100 | |||